SPRINT Share Price | Sprint Bioscience AB Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Sprint Bioscience AB with Similar Stocks

Ascelia Pharma AB Isofol Medical AB Iconovo AB

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of 723.19%, the company declared Outstanding results in Dec 25

The company has declared positive results in Jan 70 after 2 consecutive negative quarters
OPERATING CASH FLOW(Y) Highest at SEK 83.53 MM
ROCE(HY) Highest at 142.84%
RAW MATERIAL COST(Y) Fallen by -333.72% (YoY)

With ROE of -156.77%, it has a risky valuation with a 5.37 Price to Book Value

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 204 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

76.97%

Price to Book

1.71

Revenue and Profits:

Net Sales:

134 Million

(Quarterly Results - Dec 2025)

Net Profit:

113 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

44.64%

6 Months

273.21%

1 Year

218.16%

2 Years

80.11%

3 Years

342.8%

4 Years

-37.57%

5 Years

-57.85%

Sprint Bioscience AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

58.16%

EBIT Growth (5y)

34.70%

EBIT to Interest (avg)

-23.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.17

Sales to Capital Employed (avg)

5.26

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

7.10%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.37

EV to EBIT

-2.35

EV to EBITDA

-2.45

EV to Capital Employed

-5.04

EV to Sales

0.88

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-156.77%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 721.47% vs 49.54% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 2,795.24% vs 16.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "133.90",
          "val2": "16.30",
          "chgp": "721.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "117.80",
          "val2": "-5.80",
          "chgp": "2,131.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "113.20",
          "val2": "-4.20",
          "chgp": "2,795.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "877.80%",
          "val2": "-361.30%",
          "chgp": "123.91%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 154.88% vs 29.90% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 601.09% vs -4,475.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "167.20",
          "val2": "65.60",
          "chgp": "154.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "98.40",
          "val2": "-19.00",
          "chgp": "617.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "91.70",
          "val2": "-18.30",
          "chgp": "601.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "582.20%",
          "val2": "-303.70%",
          "chgp": "88.59%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

133.90

16.30

721.47%

Operating Profit (PBDIT) excl Other Income

117.80

-5.80

2,131.03%

Interest

4.70

0.00

Exceptional Items

0.00

Consolidate Net Profit

113.20

-4.20

2,795.24%

Operating Profit Margin (Excl OI)

877.80%

-361.30%

123.91%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 721.47% vs 49.54% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 2,795.24% vs 16.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

167.20

65.60

154.88%

Operating Profit (PBDIT) excl Other Income

98.40

-19.00

617.89%

Interest

6.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

91.70

-18.30

601.09%

Operating Profit Margin (Excl OI)

582.20%

-303.70%

88.59%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 154.88% vs 29.90% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 601.09% vs -4,475.00% in Dec 2024

All Annual Results

Company CV

About Sprint Bioscience AB

Sprint Bioscience AB

Pharmaceuticals & Biotechnology

Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Company Coordinates

Company Details

Novum, Halsovagen 7, Floor 8, elevator A , HUDDINGE None : 141 57

Tel: 46 8 4114455

https://www.sprintbioscience.com/

Registrar Details